Hormonal
Survodutide, a glucagon receptor/GLP-1 receptor dual agonist, induces significant body weight reduction in people with obesity and type 2 diabetes (T2D) when administered weekly via subcutaneous injection alongside lifestyle modifications.
If you have obesity and Type 2 Diabetes, standard diet and exercise changes often lead to weight regain. This trial investigates a weekly injection (survodutide) that targets both glucose and fat metabolism pathways. It is designed to be taken alongside a modest calorie deficit (500 kcal/day) and 150 minutes of weekly exercise. The dose is slowly increased to minimize stomach side effects, which are common but manageable. This approach aims to provide more durable weight loss than lifestyle changes alone, addressing the specific challenge that T2D can blunt weight loss efforts.
SYNCHRONIZE-2 will determine the efficacy, safety and tolerability of survodutide for BW reduction in people with obesity and T2D... In a Phase 2 clinical trial in people with both obesity and T2D, treatment with survodutide up to 2.7 mg once weekly or 1.8 mg twice weekly for 16 weeks induced up to an 8.7% mean reduction in BW... In a separate Phase 2 trial, treatment with survodutide 4.8 mg once weekly for 46 weeks led to an average 18.7% weight loss in people with obesity without T2D.
Why this rating
The paper is a baseline characteristics report for a Phase 3 trial; efficacy data is not yet reported, relying on Phase 2 data for efficacy claims.
Source
Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes
Sean Wharton et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70263
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →